// App-Quantinova.ai

OP0011 : A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS

Researchers

Presenter

  • P. A. Merkel

Principal Investigators

  • D. Jayne

  • H. Yue

  • T. Schall

  • C. Kelleher

  • P. Bekker

Medical Centers

  • University of Pennsylvania, Philadelphia, United States of America

  • University of Cambridge, Cambridge, United Kingdom

  • ChemoCentryx, Inc., Mountain View, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Glucocorticoid

  • Oraprine

  • Prednisone

  • Rituximab

  • CCX-168

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved